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Long-Term Survival and Local Relapse Following Surgery
Without Radiotherapy for Locally Advanced Upper
Rectal Cancer
An International Multi-Institutional Study
Jun Seok Park, MD, Yoshiharu Sakai, MD, NG Siu Man Simon, MD, Wai Lun Law, MD,
Hyeong Rok Kim, MD, Jae Hwan Oh, MD, Hester Cheung Yui Shan, MD,
Sang Gyu Kwak, MD, and Gyu-Seog Choi, MD
Abstract: Controversy remains regarding whether preoperative che-
moradiation protocol should be applied uniformly to all rectal cancer
patients regardless of tumor height. This pooled analysis was designed
to evaluate whether preoperative chemoradiation can be safely omitted
in higher rectal cancer.
An international consortium of 7 institutions was established. A
review of the database that was collected from January 2004 to May
2008 identified a series of 2102 patients with stage II/III rectal or sigmoid
cancer (control arm) without concurrent chemoradiation. Data regarding
patient demographics, recurrence pattern, and oncological outcomeswere
analyzed. The primary end point was the 5-year local recurrence rate.
The local relapse rate of the sigmoid colon cancer (SC) and upper
rectal cancer (UR) cohorts was significantly lower than that of the mid/
low rectal cancer group (M-LR), with 5-year estimates of 2.5% for the SC
group, 3.5% for the UR group, and 11.1% for the M-LR group,
respectively. A multivariate analysis showed that tumor depth,
nodal metastasis, venous invasion, and lower tumor level were strongly
associated with local recurrence. The cumulative incidence rate of local
failure was 90.6%, 92.5%, and 94.4% for tumors located within 5, 7, and
9 cm from the anal verge, respectively.
Routine use of preoperative chemoradiation for stage II/III rectal
tumors located more than 8 to 9 cm above the anal verge would be
excessive. The integration of a more individualized approach focused on
systemic control is warranted to improve survival in patients with upper
rectal cancer.
(Medicine 95(22):e2990)
Abbreviations: CRT = chemoradiotherapy, DFS = disease-free
survival, LR = locoregional recurrence, M-LR = mid/low rectal
cancer group, OR = odds ratio, OS = overall survival, SC = sigmoid
colon cancer, TME = total mesorectal excision, UR = upper rectal
cancer.
INTRODUCTION
T he last 2 decades have witnessed the development ofsurgical standards, including total mesorectal excision
(TME), which has been shown to decrease locoregional recur-
rence (LR) significantly.1,2 Several large clinical trials have
demonstrated the superiority of neoadjuvant radiotherapy with
chemotherapy over surgery alone. Preoperative chemora-
diotherapy (CRT) is also associated with higher sphincter-
saving procedures and improved local control.3–8 For patients
who are selected to receive CRT, the expected benefits and
disadvantages have to be well balanced, because pelvic radio-
therapy may be provided at the expense of increased late
morbidity and toxicity. Preoperative CRT also has major
financial implications for health care providers.
There is no agreement regarding the cutoff height from the
anal verge of the rectum at which patients would not benefit
from preoperative CRT. According to the guideline of the
National Comprehensive Cancer Network, preoperative CRT
is recommended for all rectal cancers of clinical stages II and
III, regardless of the distance between the tumor and the anal
verge.9 Previous major rectal cancer trials that assessed the
efficacy of CRT have defined rectal cancer as any tumor located
<15 or 16 cm from the anal verge, and included upper rectal
cancer.3–6,10–13 However, routine administration of CRT before
proper surgery has been questioned particularly for those with
upper rectal cancer. Several studies showed that higher rectal
cancers behave like colon cancers regarding recurrence pattern
and prognosis, and not like rectal cancer.14,15
Because of the variation in protocols regarding preopera-
tive CRT and the paucity of literature on this subject, we aimed
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to estimate the impact of omitting radiotherapy in upper rectal
cancer. Therefore, we analyzed the long-term outcomes of
upper rectal cancer and compared them with those of sigmoid
and low rectal cancer in a cohort of patients treated with a non-
preoperative CRT protocol. In addition, this study was con-
ducted to evaluate whether it is possible to establish an indi-
vidualized anatomical landmark for preoperative CRT by
assessing the difference in oncological outcomes according
to the peritoneal reflection (intraperitoneal vs extraperitoneal).
PATIENTS AND METHODS
Patients Cohort
An international consortium of 7 institutions, each of
which is a tertiary cancer center, was established. Consecutive
cases of operations performed between January 2004 and May
2008 comprised the data set for this analysis. Eligibility criteria
included biopsy-proven adenocarcinoma, with the inferior mar-
gin located within 30 cm of the anal verge. A prospectively
maintained administrative database or the hospital records of all
2962 patients with tumor stage II or III rectal and sigmoid colon
cancer were reviewed. Eight hundred sixty-four patients were
excluded for the following reasons: age >80 years (n¼ 156),
synchronous or previous history of other malignancies
(n¼ 148), emergent cases (n¼ 82), loss to follow-up within
6 months (n¼ 44), history of neoadjuvant therapy (n¼ 208) or
adjuvant radiotherapy (n¼ 144), and familial adenomatous
polyposis or hereditary nonpolyposis colorectal carcinoma
(n¼ 78). Thus, the study population consisted of 2102 patients.
Each surgeon who participated in this study provided specified
perioperative and pathological data using a common menu-
driven database file that incorporated precise coding
TABLE 1. Patient and Tumor Characteristics














64.3 (11.08) 64.8 (10.8) 64.9 (11.6) 0.62 64.7 (10.9) 64.2 (11.8) 0.45
Sex, No., % 0.96 0.71
Male 406 (59.9) 396 (60.0) 453 (59.3) 520 (60.6) 289 (59.6)
Female 272 (40.1) 264 (40.0) 311 (40.7) 338 (39.4) 196 (40.4)
Tumor height, cm 21.4 (4.6) 12.5 (2.0) 6.0 (2.2) <0.001 10.32 (2.7) 4.9 (1.9) <0.001
Tumor size, cm 4.9 (1.9) 4.8 (1.8) 4.7 (1.8) 0.34 5.0 (1.8) 4.6 (1.7) 0.003
BMI, kg/m2

23.4 (3.1) 23.3 (3.0) 23.1 (3.2) 0.27 23.2 (3.1) 23.3 (3.2) 0.74
Preoperative CEA, ng/dL

8.1 (21.0) 10.9 (46.7) 8.1 (18.4) 0.16 9.9 (40.9) 8.1 (19.3) 0.34
Surgery title, No., % <0.001 <0.001
Anterior resection 663 (97.8) 665 (99.2) 550 (72.0) 849 (99.0) 285 (58.8)
ISR with CAA 0 (0) 0 (0) 77 (10.1) 1 (0.1) 76 (15.7)
Nonsphincter preserving 15 (2.2) 5 (0.8) 137 (17.9) 8 (0.9) 124 (25.6)
Adjuvant chemotherapy, No., % <0.001 <0.001
None 306 (45.6) 316 (47.9) 459 (61.1) 432 (50.5) 289 (61.0)
First line regimeny 236 (35.2) 303 (45.9) 274 (36.5) 378 (44.2) 175 (36.9)
Second line regimenz 129 (19.2) 41 (6.2) 18 (2.4) 46 (5.4) 10 (2.1)
Lymphatic invasion, No., % <0.001 0.53
No 335 (50.1) 413 (62.7) 489 (64.3) 541 (63.1) 312 (64.9)
Yes 333 (49.9) 246 (37.3) 271 (35.7) 316 (36.9) 169 (35.1)
Venous invasion, No., % 0.04 0.23
No 516 (77.2) 545 (82.6) 617 (81.1) 718 (83.7) 391 (81.1)
Yes 152 (22.8) 115 (17.4) 144 (18.9) 140 (16.3) 91 (18.9)
Histologic grade, No., % 0.18 0.34
Well 83 (12.5) 111 (17.0) 114 (15.1) 147 (17.3) 78 (16.4)
Moderate 561 (84.7) 519 (79.5) 615 (81.7) 670 (79.0) 388 (81.3)
Poor 18 (2.7) 23 (3.5) 24 (3.2) 31 (3.7) 11 (2.3)
Stage, No., % 0.001 0.63
II 323 (47.6) 388 (58.8) 423 (55.4) 489 (57.0) 283 (58.4)
III 355 (52.4) 272 (41.2) 341 (44.6) 369 (43.0) 202 (41.6)
Residual tumor status, No., % 0.16 0.44
R0 661 (97.8) 650 (98.6) 753 (98.6) 843 (98.4) 481 (99.2)
R1 6 (0.9) 5 (0.8) 9 (1.2) 9 (1.1) 3 (0.6)
R2 9 (1.3) 4 (0.6) 2 (0.3) 5 (0.6) 1 (0.2)
BMI¼ body mass index, CAA¼ coloanal anastomosis, CEA¼ carcinoembryonic antigen, ISR¼ intersphincteric resection, R0¼ complete
excision, R1¼microscopic incomplete excision, R2¼macroscopic incomplete excision.
Values are mean (standard deviation).
yAdjuvant chemotherapy including 5-FU/leucovorin and oral capecitabine.
zAdjuvant chemotherapy including FOLFOX, XELOX, and FOLFIRI.
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instructions. The study was approved by the institutional review
board of Kyungppk National University Medical Center.
Tumor Location
The primary aims of the current analysis were to describe
and compare the 5-year LR rate of tumors according to their
location. Subgroups of particular interest were the intraper-
itoneal subset of patients compared with those with extraper-
itoneal rectal cancer. The tumor height was defined as the
distance between the tumor caudal margin and the anal verge,
and was measured by rigid sigmoidoscopy or colonoscopy.
Tumors located 15.1 to 30 cm, 10.0 to 15 cm, and 0 to 9.9 cm
from the anal verge were classified as sigmoid cancer
(SC group, control arm), upper rectal cancer (UR group,
investigational arm), and cancer of the mid- or lower-third
rectum (M-LR group, control arm), respectively. In subgroup
analysis, the final discrimination for categorization between
intraperitoneal and extraperitoneal lesions was done intrao-
peratively by identification of the anatomical differences by the
surgeon. Generally, rectal cancer was classified as extraper-
itoneal when the cranial margin of the tumor was located below
the peritoneal reflection.
Treatment Scheme
The surgical technique used at each institution was stan-
dardized in terms of the tumor-specific mesorectal excision
principle, as described previously.16–18 Although postoperative
care varied slightly across institutions, most surgeons had
established a similar protocol for postoperative treatment. Post-
operative chemotherapy was administered according to local
unit policy, predominantly Mayo regimen or oral capecitabine.
Adjuvant chemotherapy was administrated to patients with
stage III disease and to those with stage II disease with poor
clinicopathological features.
Recurrences were confirmed by pathology or conventional
imaging techniques. LR was defined as evidence of recurrent
disease within the pelvis, including recurrence at the site of
anastomosis and perineum, whereas distant metastasis was
defined as any other recurrence. The local recurrence was
further subdivided into lateral pelvic type and central type.
Lateral pelvic recurrence was defined as recurrence in the
muscle (piriformis, elevator), soft tissue of the pelvic sidewall,
lymph nodes along the iliac vessels, lateral pelvic nerve plexus,
and lateral bony pelvis. Central pelvic recurrencewas defined as
recurrence in the perianastomotic area, posterior tumor bed
(presacral), and anterior pelvic organs (bladder, prostate,
vagina, etc.).
Sample Size Calculation and Statistical Analysis
All statistical analyses were performed using the IBM
SPSS Statistics software package for Windows (IBM SPSS
Statistics version 20.0, New York, NY). Quantitative variables
were expressed as the value of mean (standard deviation) and
qualitative variables were expressed as the value of frequency
(proportion). Between-group differences for total set and sub-
group set were compared using one-way ANOVA or two-
sample t test for quantitative variables with normality and
chi-square test for qualitative variables, as appropriate. Prob-
ability of overall survival (OS) and probability of disease-free
survival (DFS) were estimated using the Kaplan-Meier method.
The log-rank test was used to compare survival rate between
groups. Minimum length of follow-up is 5 years. Selected
variables showing statistical significance in a univariate analysis
were included as covariates in multivaiate analysis, binary
multiple logistic regression. For the selection of optimal cov-
ariates in multivariate analysis, the forward conditional like-
lihood method was used. With the result of binary multiple
logistic regression, the values of odds ratio (OR), 95% confi-
dence interval of OR, and P value were presented for statisti-
cally significant variables. Propensity score matching method
used in Figure 2 are presented as a supplementary file 1, http://
links.lww.com/MD/A913. Differences were considered signifi-
cant if P< 0.05.
RESULTS
Patient characteristics are listed in Table 1. There were no
differences in most baseline variables but oxaliplatin-based
chemoregimens (i.e., FOLFOX and FOLFIRI) were adminis-
tered significantly more frequently in the SC group than in the
UR and M-LR groups (P< .001). The overall R0 resection rate
was 98.4%.
Pattern of First Failure
The median follow-up period was 79.0 months (interquar-
tile range, 62.1–97.6 months), and, in total, 540 (25.7%)
patients developed disease recurrence in 5 years after primary
surgery. The distribution of the first-recurrence events accord-
ing to tumor location is presented as supplementary Table 1,
http://links.lww.com/MD/A913. The isolated local recurrence
rate was 1.8% for the SC group, 2.7% for the UR group, and
10.8% for the LR group (P< 0.001). Regarding local relapse,
lateral pelvic recurrence was prominent in the M-LR group,
whereas relapse at the central pelvis occurred more often in the
SC and UR groups. Moreover, there were some differences
between the 3 groups regarding the pattern of distant recurrence.
FIGURE 1. Estimated local recurrence (A), disease-free survival (B), and overall survival (C) for all patients according to tumor location.
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The most common hematogenous recurrence site was the liver
in the SC group and UR group, whereas it was the lung in the
M-LR group.
Survival Outcomes
The overall 5-year LR, DFS, and OS were dependent on
tumor location (Table 2). The local relapse rate of the SC and
UR cohorts was significantly lower than that of the M-LR.
There were statistically significant differences in hazard ratios
(HRs) for LR comparison among all patients, favoring the SC
and UR groups (SC vs UR: HR, 0.583; 95% CI, 0.172–1.972;
P¼ 0.39; UR vs M-LR: HR, 0.819; 95% CI, 0.185–3.620;
P< 0.001; and M-LR vs SC: HR, 5.07; 95% CI, 2.87–8.98;
P< 0.001). Regarding DFS and OS, a Kaplan–Meier analysis
and post hoc tests showed that the curve of the UR group lay
between that of the SC and M-LR groups (Figure 1). Similar
results were also obtained for the LR, DFS, and OS rates
stratified by stage. The 5-year DFS rate for the stage III UR
group compared with the stage III SC group was 65.2% vs
78.3% (HR, 1.759; 95% CI, 1.298–2384; P< 0.001). Sub-
sequently, we specifically studied the relapse rates
according to T and N stage to identify high-risk subpopulations.
The patients with upper rectal cancer were divided into
4 groups according to TN substaging (supplementary
Table 2, http://links.lww.com/MD/A913). Among the patients
in the UR group, the T3N0, T3N1–2, T4N0, and T4N1–2
TABLE 3. Multivariate Cox Regression Analysis of Local Recurrence Risk Among Patients With Rectal Cancer
Univariate Multivariate
Variable HR P HR 95% CI P
Sex
Male 1 — 1 — — —
Female 1.556 0.048 1.579 0.909–2.745 0.11
Age, y
<70 1 — 1 — — —
70 1.338 0.20 1.238 0.703–2.180 0.46
BMI, kg/m2
<27.5 1 — 1 — — —
27.5 2.112 0.04 2.087 0.973–4.478 0.06
Baseline CEA, ng/dL
<7 1 — 1 — — —
7 1.348 0.69
Completeness of excision
R0 1 — 1
R1–2 0.907 0.93
Distal resection margin, cm
1 1 — 1 — — —
<1 2.018 0.01 1.535 0.740–3.184 0.25
Tumor size, cm
<5 1 — 1
5 0.974 0.91
Lymphatic invasion
No 1 — 1 — — —
Yes 1.937 0.003 0.891 0.480–1.653 0.71
Histologic grade




No 1 — 1 — — —
Yes 2.367 <0.001 2.122 1.096–4.108 0.03
Mesenteric LN metastasis
N0 1 — 1 — — —
N1 1.932 0.01 1.705 0.898–3.237 0.10
N2 2.648 0.001 2.298 1.079–4.892 0.03
Depth of tumor
T1–3 1 — 1 — — —
T4 2.370 0.007 3.232 1.515–6.895 0.002
Tumor location
Upper rectum 1 — 1 — — —
Mid/low rectum 4.130 <0.001 4.247 2.178–8.282 <0.001
BMI¼ body mass index, CEA¼ carcinoembryonic antigen, CI¼ confidence interval, HR¼ hazard ratio.
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subgroups exhibited a 5-year LR of 1.2%, 5.7%, 5.6%, and
17.2%, respectively.
Multivariate Analysis and Estimated Cumulative
Incidence of Local Recurrences
The results of the univariate analysis of risk factors for
local relapse are given in Table 3. The multivariate analysis of
local recurrence selected the following 4 independent risk
factors: venous invasion, involvement of lymph nodes, T4 depth
of the tumor, and lower tumor location. Using the confounding
factor obtained from the multivariate analysis, a statistical
model was created to estimate each cumulative incidence rate
of LR according to tumor height. As we control potential
confounding variables, the cumulative incidence rate of LR
was 90.6%, 92.5%, and 94.4% for tumors located within 5, 7,
and 9 cm of the anal verge, respectively (Figure 2).
Subgroup Analysis: Intraperitoneal Versus
Extraperitoneal Rectal Cancer
After excluding sigmoid colon cancer, a subgroup analysis
was performed to compare oncological outcome between tumor
with extraperitoneal and those with intraperitoneal rectal
cancers; the cancers were categorized according to peritoneal
reflection. The most common hematogenous recurrence site in
the intraperitoneal rectal group was the liver, whereas it was the
lung in the extraperitoneal group. Significant differences in LR
and DFS rates were found between intraperitoneal versus
extraperitoneal tumors (P< 0.05) (Figure 3).
DISCUSSION
Compared with the Western countries, preoperative che-
moradiation has been introduced relatively late in the majority
region of Asia. Indeed, preoperative CRT has been gradually
integrated into the protocol of locally advanced rectal cancer
management since the mid-2000s at these 7 institutions. During
the study period, their use was limited to highly selected patients
(advanced T4 tumor, clinical involvement of resection margin),
thus providing a unique opportunity to compare sigmoid colon
and upper rectal cancer with low rectal cancer directly, without
confounding from radiation therapy. Without pelvic radiother-
apy, LR rates of 1.7% and 5.9% were achievable in pathologi-
cally proved stage II and stage III cancer of the UR group,
respectively. The statistical model for cumulative incidence rate
of local relapse displayed a stronger linear association between
tumor height and events. Higher lesions, which were located>9
cm from the anal verge, accounted for only 5.6% of all local
failure. Taken together, these results lead us to believe that the
absolute benefit of preoperative CRT in locally advanced upper
rectal cancer may be small, if present.
The majority of surgeons consider that high rectal cancers
should be treated according to the colon cancer guidelines. This
treatment strategy is based on the hypothesis that cancers
located in the upper third of the rectum behave more like colon
cancer from a technical and anatomical perspective. Although
TME has become a standard of care for rectal cancer, several
conditions inevitably escape the TME field, for example, higher
involvement rate of circumferential radial margin, potential
microscopic tumor cell infiltration in pelvic soft tissue, and
lateral spread of pelvic lymph nodes.3,19 Therefore, preopera-
tive or postoperative adjuvant treatment has been added to
TME. In contrast to low and middle tumors, which are con-
strained by a restrictive pelvis, upper rectal cancers are not
bound by similar physical limitations. Several studies have
shown that upper rectal cancer should be treated using the
same technique (partial mesorectal excision) as sigmoid colon
cancer, whereas TME should be performed for middle and low
rectal cancers.17,20 In addition, one could argue that the lym-
phatic spread pattern of upper rectal cancer is different from that
of mid or low rectal tumors. Lymphatic drainage from the upper
FIGURE 2. Predicted model for cumulative local relapse rate
according to the tumor height: A, curve was drawn using raw
data; B, curve was drawn after removing effects of 3 variables,
venous invasion, mesenteric LN metastasis, and depth of tumor
that were statistically significant in multivariate analysis; at last, C,
curve was drawn after removing effects of all variables.
FIGURE 3. Estimated local recurrence (A), disease-free survival (B), and overall survival (C) for subgroup analysis: intraperitoneal versus
extraperitoneal tumor.
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rectum proceeds mostly along the superior rectal artery to the
inferior mesenteric vessels. Conversely, the lower rectum has an
additional portion that may drain laterally through the internal
iliac system to the lateral pelvic sidewall.21,22 The incidence of
lateral lymph node metastasis ranges from 8.6% to 27%, and
such nodes are a major cause of local recurrence, even after
preoperative CMT combined with TME.21,23–25 In our series,
the lateral pelvic recurrence rate was 1.2% in patients with
upper rectal cancer, and 7.3% in those with middle and lower
rectal cancer. Our findings are consistent with those of prior
studies, as they indicate that the incidence of lateral lymph node
metastasis increases with decreasing distance of the tumor from
the anal verge.21,26
There is some discrepancy in the impact of pelvic radio-
therapy in upper rectal cancer between the historical random-
ized trials. Recently, the German Rectal Cancer Study Group
(CAO/ARO/AIO-94) reported long-term results of that trial
after a median follow-up of 134 months.5 The study population
was composed of patients with T3/4 tumors that were diagnosed
using endorectal ultrasound and computed tomography, 15% of
whom had upper rectal lesions (>10 cm from the anal verge).
The authors found a 10-year local recurrence of 4.3% in upper
rectal tumors with preoperative CMT compared with 10.4% in
the nonirradiated group. AMedical Research Council study also
reported a reduction of the local recurrence rate after radio-
therapy in patients with upper-third rectal cancer (1.2% with
preoperative CRT vs 6.2% after selective postoperative CRT).6
In contrast, 2 other clinical trials reported results that support the
hypothesis that preoperative CRT does not confer much
additional benefit for upper rectal cancer. The subgroup
analysis of the Swedish Rectal Trial and the Dutch TME trial
proved the clinical efficacy of neoadjuvant CRT for mid and
low rectal tumors; however, its effect on upper rectal lesions
was not significant.4,27 None of the aforementioned trials
focused on, or were powered, to evaluate the impact of radiation
in the subset of patients with upper rectal tumors. In fact, the
German Rectal Cancer Study Group performed subgroup
analyses for upper lesions, included sample sizes between 45
and 85 patients according to treatment arms, and may have
been underpowered.
An unexpected finding of the present study was that
patients with sigmoid cancer showed a trend of improvement
of the estimated disease-free survival and overall survival
compared with cancers of the upper-third rectum. We postulate
that these differences may have been caused by the adjuvant
chemotherapy setting and the heterogenetic biological features
of upper rectal cancer. During the study period, and in the
setting of colon cancer, advanced drugs (including oxaliplatin,
irinotecan, and the target agents) were established as a new
standard regimen for stage III colon cancer. In contrast, the
identification of optimal adjuvant chemotherapy protocols for
rectal cancer has been complicated by the fact that most large
clinical studies were conducted based on a neoadjuvant CRT
setting.28,29 Indeed, in our series, a more aggressive chemoregi-
men was administered to the colon cancer cohort approximately
3 times more often than it was to the upper rectal cancer group.
The decision to administer radiation therapy based solely on
numerical tumor height involves anatomical pitfalls. As con-
ventionally described, the peritoneum runs obliquely and down-
ward from the posterior reflection to the anterior reflection.30
Rectal cancers located 6 to 12 cm from the anal verge can
be intraperitoneal tumors that would be too mobile to be
reliably targeted with radiation or extraperitoneal tumors that
should be amenable to radiotherapy.30–32 Therefore, some
surgeons propose that peritonealization might be the individua-
lized landmark for the selection of the upper boundary of the
radiation field. In our subgroup analysis, the overall 5-year local
recurrence rate in the intraperitoneal and extraperitoneal groups
was 4.2% and 13.3%, respectively. More important, blood-borne
metastases or disseminated disease predominated among intra-
peritoneal rectal tumors, whereas local failure wasmore frequent
among tumors involving the area below the peritoneal reflection.
In future studies, the authors plan to elucidate whether the
peritoneal reflection is an individualized landmark that facilitates
the selection of patients for preoperative CRT.
There were several limitations to this study. First, because
of its retrospective nature, the impact of preoperative CRT on
rectal cancer was not addressed adequately in this series. We
were not able to compare protocol-for-protocol long-term out-
comes between patients who did and those who did not undergo
radiation therapy in addition to surgery, because only a very few
patients (<4%) with upper rectal cancer received radiotherapy
during the study period. Second, our analysis was performed
using only Asian populations from 3 countries. Therefore,
further validation using cohorts with different ethnicities or
geographic locations would be recommended.
In conclusion, this study provided further evidence that
omission of preoperative CRT may not represent undertreat-
ment in locally advanced upper rectal cancer. The systemic
control of micrometastasis and accurate pretreatment identifi-
cation of high-risk T4 tumors may represent the next break-
through in the management paradigm of upper rectal cancer.
The definition in greater detail of the oncological implications
of peritoneal reflection may allow the application of patient-
tailored treatment strategies to advanced rectal cancer in
the future.
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